U.S. Metals and Mining Stock News

NasdaqGS:COCO
NasdaqGS:COCOBeverage

Is Vita Coco (COCO) Using Sweeter Treats To Redefine Its Margin Story?

In early March 2026, The Vita Coco Company expanded its Vita Coco Treats line with a new Frosted Lemonade flavor and a Cherry Vanilla exclusive at Target, adding coconutmilk-based indulgent options now available across major retailers and online channels. This push into sweeter, treat-oriented beverages highlights Vita Coco’s effort to tap demand for mindful indulgence while broadening its coconut-based product occasions beyond traditional hydration. We’ll now examine how this expansion of...
NYSE:BYD
NYSE:BYDHospitality

A Look At Boyd Gaming (BYD) Valuation After Recent Share Price Moves

Event context and recent share performance Boyd Gaming (BYD) has drawn investor attention after recent share price moves, with the stock up about 2.2% over the past day and 2% over the past week, while returns for the month and past 3 months have been slightly negative. See our latest analysis for Boyd Gaming. That short burst of share price strength comes against a softer backdrop, with a year to date share price return of around 5% decline, while the 1 year total shareholder return is...
NYSEAM:IE
NYSEAM:IEMetals and Mining

Ivanhoe Electric (IE) Is Down 10.7% After US$58.4 Million Cash Inflow From Cordoba Distribution – Has The Bull Case Changed?

Ivanhoe Electric recently disclosed that it will receive about US$58.4 million in cash from its 59.6%-owned subsidiary Cordoba Minerals, following Cordoba’s sale of its remaining interest in the Alacrán Project in Colombia and subsequent shareholder distribution completed in March 2026. This one-off inflow meaningfully lifts Ivanhoe Electric’s liquidity, giving the company additional room to fund its critical metals exploration and development plans without immediate reliance on external...
NasdaqGS:CMTL
NasdaqGS:CMTLCommunications

Comtech Telecommunications (CMTL) Loss Of US$19.8 Million Keeps Turnaround Narratives Under Pressure

Comtech Telecommunications (CMTL) has just posted Q2 2026 results that keep the focus squarely on profitability, with Q1 2026 revenue of US$111.0 million, a basic EPS loss of US$0.67, and net income loss of US$19.8 million. Over recent quarters the company has seen revenue move from US$115.8 million and an EPS loss of US$52.93 in Q1 2025 to US$130.4 million and an EPS loss of US$0.39 in Q4 2025, with net income losses shifting from US$155.9 million to US$11.6 million across the same period...
NYSE:TOST
NYSE:TOSTDiversified Financial

Should Toast’s Teriyaki Madness Win Shape How Investors View TOST’s Enterprise Growth Story?

In March 2026, Teriyaki Madness announced it had implemented Toast’s enterprise technology suite, including Toast Flex hardware and Kitchen Display Systems, across its more than 200 US locations to support its expanding operations and integrate its full tech stack. This win highlights Toast’s growing presence with larger, multi-location restaurant brands, underscoring the appeal of its integrated platform for chains seeking scalable, end-to-end digital infrastructure. Next, we’ll examine how...
NYSE:LDOS
NYSE:LDOSProfessional Services

A Look At Leidos Holdings (LDOS) Valuation After New Defense Cloud And AI Cybersecurity Wins

Why the new contracts matter for Leidos Holdings stock Leidos Holdings (LDOS) has attracted fresh attention after securing a US$454.9 million contract to modernize the U.S. Air Force's Cloud One platform and announcing a partnership with Dropzone AI focused on federal cybersecurity. Together, these agreements tie the company more tightly to U.S. defense cloud and cyber operations, giving investors fresh information to weigh alongside recent share performance and existing government focused...
NasdaqGS:GLUE
NasdaqGS:GLUEBiotechs

Monte Rosa Therapeutics (GLUE) Quarterly Loss Tests Bullish Profitability Narrative

Monte Rosa Therapeutics (GLUE) just posted its FY 2025 third quarter numbers, with revenue of US$12.8 million and a basic EPS loss of US$0.33 off a net income loss of US$27.1 million, setting a clear snapshot of where the business stands today. Over recent periods, the company has seen revenue move from US$60.6 million in Q4 2024 to US$84.9 million in Q1 2025, then to US$23.2 million in Q2 2025 and US$12.8 million in Q3 2025. Over the same timeframe, basic EPS shifted from a profit of US$0.16...
NYSE:TAP
NYSE:TAPBeverage

Is Molson Coors (TAP) Quietly Redefining Its Brand With Higher-ABV Flavored Alcohol Bets?

In March 2026, Molson Coors Beverage Company expanded its portfolio with the nationwide launch of Simply Spiked Bolder Strawberry Lemonade, a 12% ABV flavored alcoholic beverage sold in 7.5 oz mini cans and 12-packs for at-home and on-the-go occasions. This higher-ABV, ready-to-enjoy product directly targets demand for more intense flavor and convenience, underscoring Molson Coors’ push beyond traditional beer into flavored alcohol categories. Now we’ll examine how this higher-ABV Simply...
NYSE:LNG
NYSE:LNGOil and Gas

Cheniere Talks With Thailand Spotlight LNG Flexibility And Valuation Opportunity

Cheniere Energy (NYSE:LNG) is in talks with Thailand to adjust existing LNG contracts to increase and speed up cargo deliveries. The discussions are tied to supply disruptions linked to a force majeure event affecting LNG exports from Qatar. Thailand is seeking more volume and faster arrival of LNG cargoes as it responds to tighter regional gas supply conditions. Cheniere Energy is a major US LNG exporter, with contracts supplying buyers across Asia and Europe. The current talks with...
NasdaqGM:ANIP
NasdaqGM:ANIPPharmaceuticals

Is ANI Pharmaceuticals (ANIP) Pullback Hiding A Contradiction In Its Valuation Story

If you are wondering whether ANI Pharmaceuticals at around US$74.28 is offering fair value or a potential mispricing, it helps to step back and look at the full return and valuation picture. The share price has seen a 2.2% decline over the past week and a 4.0% decline over the past month, while still recording a 15.7% return over 1 year and an 86.4% and 132.1% return over 3 and 5 years respectively. Recent news coverage has focused on ANI Pharmaceuticals as part of broader discussions around...
NasdaqGS:TTWO
NasdaqGS:TTWOEntertainment

WWE 2K26 Launch Tests Take Two Valuation And Growth Expectations

2K, a label under Take-Two Interactive Software, has announced WWE 2K26 with expanded editions and new gameplay features. The title is planned for broad platform availability, including tailored support for Nintendo Switch 2 hardware. WWE 2K26 will feature the largest roster in the franchise so far and a slate of post-launch content. For investors tracking NasdaqGS:TTWO, WWE 2K26 arrives as a fresh entry in a key licensed sports entertainment series, adding to Take-Two Interactive...
NYSE:TKR
NYSE:TKRMachinery

A Look At Timken (TKR) Valuation As Short Term Momentum Softens And Long Term Returns Hold Up

Timken (TKR) is back on investor radar after recent share price moves, with the stock around US$98.59 and short term performance mixed between daily, weekly and month returns. See our latest analysis for Timken. Recent share price moves at around US$98.59 come after a 30 day share price return of an 8.58% decline, in contrast with a 90 day share price return of 17.17% and a 1 year total shareholder return of 34.41%. This indicates fading short term momentum alongside a stronger longer term...
OTCPK:EMYB
OTCPK:EMYBBanks

Embassy Bancorp (EMYB) Net Interest Margin Improvement Tests Long Term Earnings Decline Narrative

Embassy Bancorp (EMYB) has posted a clean set of Q3 2025 numbers, with total revenue of US$11.7 million and basic EPS of US$0.50, against a 12 month backdrop where revenue on a trailing basis moved from US$39.8 million to US$44.0 million and EPS from US$1.37 to US$1.68. The latest quarter sits within a year where earnings grew 21.3% versus the longer term trend and sets the stage for investors to focus on how a 29.1% net margin and a 2.58% net interest margin shape the quality and resilience...
NasdaqGS:ACIW
NasdaqGS:ACIWSoftware

Can ACI Worldwide’s (ACIW) New Cloud-Native Card Hub Subtly Reshape Its Long-Term Payments Moat?

In early March 2026, ACI Worldwide launched ACI Connetic for Cards, a next-generation, fully integrated, cloud-native card payments suite within its ACI Connetic platform, unifying account-to-account payments, card processing and AI-driven fraud prevention on a single enterprise-grade hub. This move gives banks and payment providers a modular way to modernize card operations and consolidate issuing, acquiring, ATM and fraud capabilities as global card transaction volumes keep expanding. Now...
NasdaqGS:KSPI
NasdaqGS:KSPIConsumer Finance

Kaspi.kz (NasdaqGS:KSPI) Margin Compression Challenges Bullish Growth Narratives In FY 2025 Results

Kaspi.kz (NasdaqGS:KSPI) has posted its FY 2025 results with Q4 revenue at KZT 1.1t and net income at KZT 276,983 million, translating into basic EPS of KZT 1,451.81, against a backdrop of trailing 12 month revenue of KZT 4.0t and net income of KZT 1,073,177 million. Over recent periods, the company has seen revenue move from KZT 744,178 million in Q4 2024 to KZT 1,146,548 million in Q4 2025, while quarterly basic EPS shifted from KZT 1,641.41 to KZT 1,451.81 and trailing basic EPS moved from...
NYSE:QTWO
NYSE:QTWOSoftware

Insider Selling At Q2 Holdings Versus Analyst And Valuation Upside Estimates

Q2 Holdings (NYSE:QTWO) has seen a pattern of insider selling over the past year, with no insider share purchases reported in the same period. Most recently, General Counsel Michael Kerr sold company shares, adding to the ongoing insider selling trend. This activity comes as Q2 Holdings continues to operate as a provider of digital banking and financial experience software for banks and credit unions. Q2 Holdings focuses on cloud based digital banking platforms that help financial...
NasdaqGS:BDTX
NasdaqGS:BDTXBiotechs

Black Diamond Therapeutics (BDTX) Profit Swing To US$0.81 EPS Challenges Bearish Earnings Narratives

Black Diamond Therapeutics (BDTX) just posted a sharp swing into profit for FY 2025, with first half revenue of US$70 million translating to basic EPS of US$0.81, compared with losses in both halves of FY 2024. Over the past year, the company has seen revenue move from US$0 to US$70 million while basic EPS has shifted from losses of US$0.71 and US$0.56 in FY 2024 to a trailing 12 month figure of US$0.25. This sets up a results season where investors will focus squarely on how durable these...
NasdaqGS:IDXX
NasdaqGS:IDXXMedical Equipment

Should IDEXX’s Earnings Beat and Higher Guidance Require Action From IDEXX Laboratories (IDXX) Investors?

Earlier this year, IDEXX Laboratories reported quarterly results that exceeded Wall Street expectations and raised its full-year guidance, underscoring robust demand for its veterinary diagnostic solutions and strength in pet healthcare. This performance highlights how IDEXX’s recurring revenue model and profitable diagnostics business can translate operational momentum into stronger earnings visibility. Next, we’ll examine how this earnings beat and upgraded guidance may reshape IDEXX’s...
NasdaqGS:STOK
NasdaqGS:STOKBiotechs

Stoke Therapeutics (STOK) Quarterly Losses Test Newly Profitable Trailing Earnings Narrative

Stoke Therapeutics (STOK) has reported FY 2025 results that feature a wide range of quarterly outcomes. Q1 revenue was US$158.6 million with EPS of US$1.95, followed by Q2 revenue of US$13.8 million and an EPS loss of US$0.40, and Q3 revenue of US$10.6 million with an EPS loss of US$0.65. Over recent periods the company has seen revenue move between US$4.8 million and US$158.6 million per quarter, while EPS has shifted from a US$2.07 loss in FY 2024 to a US$1.95 profit and then back into...
NasdaqGM:WW
NasdaqGM:WWConsumer Services

WW International (WW) Q3 Loss Challenges Bullish Narrative Built On One Off US$1.1b Gain

WW International (WW) has just posted its FY 2025 results with Q3 revenue of US$172.1 million and a basic EPS loss of US$1.04, set against a trailing 12 month net income of about US$1.1 billion that reflects a large one off gain. Over recent quarters the company has seen revenue move between US$184.4 million and US$202.1 million, while EPS has swung from a profit of US$0.31 to a loss of US$0.91 and then a very large profit of US$15.71. This pattern points to margins that appear to be heavily...
NYSE:SVV
NYSE:SVVMultiline Retail

How Investors Are Reacting To Savers Value Village (SVV) Strong U.S. Comps And Insider Share Sales

Earlier this week, Savers Value Village reported preliminary fourth-quarter results showing an 8.8% rise in U.S. comparable sales and 0.7% growth in Canada, while President and COO Jubran N. Tanious exercised options for 100,000 shares at US$1.41 and sold 45,000 shares for about US$373,644 on March 11, 2026. This combination of stronger U.S. store performance and fresh insider share activity offers investors new information on both operational momentum and executive incentives. We’ll now...
NasdaqCM:VALU
NasdaqCM:VALUCapital Markets

Value Line (VALU) Earnings Decline Reinforces Bearish Narrative On Long Term Profit Trends

Q3 2026 snapshot: Value Line (VALU) leans on margins as earnings trends soften Value Line (VALU) has just reported its Q3 2026 results, with recent quarters showing revenue around US$8.6 million and basic EPS between US$0.42 and US$0.69, while trailing twelve month EPS sits a little above US$2.25. Over the last six reported quarters, revenue has ranged from US$8.39 million to US$8.97 million and basic EPS has moved between US$0.42 and US$0.69, setting up a picture where high profitability...
NasdaqCM:COYA
NasdaqCM:COYABiotechs

Coya Therapeutics (COYA) Deepening Losses Challenge Bullish Growth Narrative After FY 2025 Results

Coya Therapeutics (COYA) has released its FY 2025 results, reporting fourth quarter revenue of US$4.0 million and a basic EPS loss of US$0.34, alongside trailing twelve month revenue of US$7.9 million and a basic EPS loss of US$1.27. The company’s revenue increased from US$0.00 million in the third quarter of 2024 to US$3.6 million in the third quarter of 2025, while quarterly basic EPS has ranged from a loss of US$0.44 in the first quarter of 2025 to a loss of US$0.13 in the third quarter of...
OTCPK:ZOMD.F
OTCPK:ZOMD.FMedical Equipment

Zomedica (OTCPK:ZOMD.F) Q3 Loss Of US$6.1 Million Tests Profitability Concerns

Zomedica (OTCPK:ZOMD.F) has reported its FY 2025 third quarter with total revenue of US$8.1 million and a basic EPS loss of US$0.006, alongside a net loss of US$6.1 million. Over recent quarters, revenue has moved from US$6.1 million in Q2 2024 to US$6.5 million in Q1 2025 and US$8.1 million in Q3 2025, while quarterly net losses have ranged from US$6.1 million to US$63.8 million and trailing twelve month revenue has reached US$29.5 million against a trailing net loss of US$84.5 million. For...